The purpose of this study is to estimate the prevalence of genetic variants associated with liver disease in participants who are known, or are likely to have NAFLD.
Study Type
OBSERVATIONAL
Enrollment
830
No investigational medicinal product will be administered as a part of this study.
Research Centers of America, LLC
Hollywood, Florida, United States
PRA Health Sciences
Lenexa, Kansas, United States
Endeavor Clinical Trials, LLC
San Antonio, Texas, United States
Prevalence of Genetic Variants Associated with NAFLD
Genotyping for known mutations associated with NAFLD will be conducted and the prevalence in the overall population enrolled will be calculated.
Time frame: Up to 8 weeks
Liver Fat Content Estimated with Fibroscan
Fibroscan will be performed to obtain the controlled attenuation parameter (CAP) score to estimate liver fat content. Number of participants with a CAP score greater or equal to (\>=) 310 decibels per minute (dB/m) (that is, liver fat \>= 10 percent \[%\]) will be estimated.
Time frame: Up to 8 weeks
Liver Fibrosis Estimated with Fibroscan
Fibroscan will be conducted to obtain liver stiffness measurement to estimate liver fibrosis. Number of participants with absent, low or moderate fibrosis (that is, less than or equal to (\<=) 9 kilopascals \[kPa\]) will be estimated.
Time frame: Up to 8 weeks
Hepatic Fat Fraction
The liver fat fraction will be obtained by magnetic resonance imaging-proton density fat fraction (MRI-PDFF) to estimate the inter-participant variability in liver fat measurement.
Time frame: Up to 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.